Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I) by Shanmugam, Ganesh & Ali, Imtiaz S
  Current Cardiology Reviews, 2009, 5, 343-349  343 
 
  1573-403X/09 $55.00+.00  © 2009 Bentham Science Publishers Ltd. 
Surgical Ventricular Restoration: An Operation To Reverse Remodeling - 
The Basic Science (Part I) 
Ganesh Shanmugam and Imtiaz S. Ali
* 
Department of Surgery, Division of Cardiac Surgery, Dalhousie University, QEII Health Sciences Centre, Halifax 
Infirmary, 1796 Summer Street, Halifax, Nova Scotia B3H 3A7, Canada 
Abstract: Congestive heart failure as a consequence of ischemic heart disease is an increasing medical problem. 
Notwithstanding the huge advances in the medical and conventional surgical management of heart failure, eventual 
outcomes remain suboptimal. This 2 part article outlines the magnitude of the problem, the limitations of conventional 
therapies as they exist, and the use of newer procedures that directly address the restoration of ventricular pump function.  
The first part of the article deals with the pathology of different facets of the remodeling process, and the unique anatomy, 
geometry and flow dynamics as they pertain to ventricular function in the normal as well as the failing heart. It then 
details the limitations of conventional therapy, thereby laying the basis for the need and evolution of newer surgical 
procedures and ends with the selection of patients for ventricular restoration procedures and the pitfalls in the choice of 
patients for such newer techniques.  
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1. INTRODUCTION 
  Heart failure [HF] affects approximately 5 million 
Americans [1] and claims 700,000 lives a year, 
notwithstanding the wealth of resources expended in 
addressing this problem. HF may be systolic or diastolic. 
The commonest cause of systolic HF is ischemic heart 
disease [IHD]. Coronary artery disease [CAD], myocardial 
infarction [MI], and subsequent ischemic cardiomyopathy is 
the etiology of congestive heart failure [CHF] in 
approximately two thirds of existing cases [2]. IHD may 
result in left ventricular [LV] systolic dysfunction due to 
myocardial stunning, hibernation or infarction. In contrast to 
stunning and hibernation, LV systolic dysfunction after 
myocardial infarction is characterized at least partly by 
nonviable myocardium which may not improve with 
revascularization.  
2. REMODELING 
  Acute MI causes sequential myocyte necrosis from 
endocardium to epicardium. [3]. Emergent revascularization 
by thrombolysis, percutaneous transluminal coronary 
angioplasty [PTCA] or coronary artery bypass grafting 
[CABG], salvages epicardial muscle but does not prevent 
necrosis of the inner and mid myocardial layers if reflow is 
delayed. Consequently, transmural infarction and dyskinesia 
are uncommon. Instead the myocardium retains its thickness 
and becomes akinetic. Unfortunately infarct zone change 
from dyskinesia to akinesia does not always improve 
regional contractility  
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2A. Mechanical Remodeling 
  The geometric adaptations following acute MI constitute 
LV remodeling and are characterized by increases in LV 
end-diastolic and systolic volumes, wall thinning, increased 
sphericity and progressive worsening of cardiac function 
resulting in CHF [4,5]. Ventricular remodelling involves 
structural, cellular, extracellular, molecular, biochemical and 
metabolic mechanisms. Variables that determine LV 
remodeling include infarct size, transmurality, infarct 
location, loading conditions, previous scarring and 
revascularization [5]. Post infarct remodeling includes: (1) 
non-contractile and potentially expanding scar in the 
infarcted zone, (2) the volume load induced by such 
expansion and (3) the pressure load induced by the increased 
volume load. Additional ischemic insults contribute to 
remodeling. Thus, a mixed pressure and especially volume 
load exists [6, 7] with remodelling, with a consequent fall in 
EF in proportion to infarct size [8]. LV dilatation augments 
stroke volume by the Starling mechanism to maintain cardiac 
output. Early ventricular dilation is an adaptive mechanism, 
is beneficial and promotes survival but has deleterious long-
term hemodynamic consequences.  
  Dilatation increases wall tension by Laplace's law. LV 
wall stress/tension is proportional to the radius and pressure 
within the LV chamber and inversely proportional to LV 
wall thickness. Increasing LV volume translates to 
increasing myocyte stress, which impedes effective 
contraction. The augmented wall stress results in increased 
oxygen consumption, decreased subendocardial blood flow 
and reduced systolic shortening. LV function may deteriorate 
toward cardiogenic
  shock in the early phase or may 
eventually lead to severe HF. Increased sphericity leads to 
MR. LV dilatation and MR are linked in a vicious cycle 
whereby MR causes dilation that in turn changes ventricular 
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unifying geometric concept that arises from ischemia, valve 
insufficiency or myocyte disease. 
  LV dilatation in ischemic cardiomyopathy falls into three 
categories: 
a  Dyskinetic aneurysms from extensive scar in the 
absence of reperfusion - The commonest cause of an LV 
aneurysm is acute occlusion of the LAD, with aneurysm 
formation in the anterior wall and septum. Development 
of a LVA leads to heart failure, VT and thromboembolic 
events.  
b  Akinetic extensively scarred regions following early 
reperfusion with epicardial salvage and  
c  Akinetic areas occurring late due to remote muscle 
dilation after early aneurysm formation - These patients 
have significantly dilated poorly contracting left ventri-
cles but without massive scars.  
2B. The Biomechanical Model of HF 
  Medical therapy acting against neurohumoral activation 
slows progression but fails to arrest remodeling. When LV 
volume has increased beyond a certain extent and the 
geometry is markedly abnormal, HF progresses indepen-
dently of neurohumoral activation, according to the bio-
mechanical model of HF expressed by Mann and Bristow 
[9]. 
  At some point in the natural history of the disease, a 
transition occurs that takes the disease beyond the limits of 
conventional medical or surgical therapy. The concept of a 
biomechanical model of HF introduces the need for 
procedures such as SVR that reduce LV volumes and restore 
geometry.  
2C. Electrical Remodeling 
  Ischemic cardiomyopathy [ICMPY] is characterized by 
inter and intraventricular conduction delay. Interventricular
 
conduction delay produces RV-LV dyssynchrony. Electrical 
resynchronization
  improves LV performance by avoiding 
right ventricular
 septal displacement and limiting
 presystolic 
MR [10-12]. 
  
  LV dyssynchrony may involve different components of 
the LV
 mass to produce intraventricular dyssynchrony [13] 
Ischemic scar causes tissue inhomogeneity in dyskinetic and 
akinetic muscle, where
 non-uniform contraction, relaxation 
and filling may develop, thereby contributing to deterioration 
of global systolic and diastolic
 function.  
2D. Mechanical Performance in Ischemic Cardiomyo-
pathy 
  Systolic lengthening occurs during the isovolumic phase 
and is caused by stretching of the ischemic/scarred segments
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by the adjacent normally contracting segments.
  Energy is 
expended as normal segments contract to produce pressure. 
The ischemic/scarred segment
 is unable to generate sufficient 
tension and thus passively
  bulges. The consequence is 
dissipation and wasting of energy
  produced by normal 
segments, which stretch the ischemic/scarred
  tissue and 
therefore does not contribute to ejection [14].
. 
  Pressure volume loops show abnormalities in morpho-
logy,
 size and orientation. The most common abnormalities
 
are early shortening and early relaxation, with markedly 
reduced
 effective work. Early shortening occurs
 because of 
the unloading effect of dyskinetic myocardium, which acts 
as an elastic slack element during isovolumic contraction 
[15]. Within each cardiac cycle, regional P/L loops move in 
an opposite
  direction and asynchronously. Each region 
therefore produces a different
 contribution to global ejection.
  
2E. Neurohumoral Activation 
  Remodeling involves concomitant neurohumoral activa-
tion, which is characterized by increased plasma norepine-
phrine [NE], renin (PRA) [16], angiotensin [A-II] [17] and 
BNP [18]. The schematic details the genesis of LV dys-
function in a dilated ventricle [19]. 
3. THE IMPACT OF VOLUME 
  LV dilatation (defined as >20% increase in end diastolic 
volume) occurs in approximately 20% of infarcted patients 
as shown by Gaudron [20], Bolognese [21], the TOAT study 
[22] and the SAVE study [23]. Normal left ventricular 
endsystolic volume index [LVESVI] is less than 30 ml/m
2. 
The hallmark insight into the importance of using ventricular 
volume rather than EF to prognosticate post MI survival 
comes from White’s [24] analysis, which showed that 
patients with LVESVI >60 ml/m
2 have approximately a 
fivefold increase in mortality compared with those with 
normal volumes after infarction.  
  The GUSTO I trial showed that among infarction patients 
with successful thrombolysis, 17% had progressive LV 
enlargement above 40 ml/m
2. Mortality at one year was 16% 
among those with LVESVI 40 to 50 ml/m
2, 21% with 
LVESVI 50 to 60 ml/m
2 and 33% when LVESVI >60 ml/m
2 
[25]. 
4. RESPONSE TO CORONARY SURGERY 
  Ventricular size determines prognosis after successful 
revascularization. Wall motion, ejection fraction and 
LVESVI improve if initial LVESVI is <75  ml/m
2, but 
progressively deteriorate when pre-operative LVESVI is 
>75 ml/m
2 despite open grafts [26].  
  The importance of volume reduction is emphasized by 
Yamaguchi  et al. [27] who analyzed the impact of LV 
volume on operative results for CABG in ischemic cardio-
myopathy, and concluded that LVESVI greater than 
100 ml/m
2 independently predicted postoperative heart 
failure. 
  The underlying principle of the STICH (Surgical 
Treatment for Ischemic Heart failure) trial involves recog-
nition of the potentially lethal complications of enlarging 
ventricular volume.  
5. IMPACT OF SHAPE 
  LV shape change from elliptical to spherical, reduces 
systolic torsion, as the myofibrils shift from their normal 
oblique axis toward a more transverse direction. The normal 
myofibril shortening of 15% generates a global EF of only 
30% in spherical ventricles, compared to an EF of 60% in 
elliptical ventricles with natural torsion [28].  
  Large anterior infarctions compromise LV torsion, which 
is the fundamental mechanism “squeezing” the LV cavity to 
cause ejection. Compromised LV torsion thus leads to heart 
failure. Posterior MI’s produce posterior papillary muscle 
dysfunction and/or posterior wall motion abnormalities, 
thereby causing MR.  
6. SVR ANATOMY 
  Torrent-Guasp proposed a challenging and very impor-
tant anatomic concept in which both ventricles are con-
sidered to consist of a single myocardial band extending 
from the right ventricular muscle just below the pulmonary 
artery to the left ventricular muscle where it attaches to the 
aorta [29, 30]. The structural components include a hori-
zontal or transverse fibre orientation for the basal loop that 
surrounds the right and left ventricles, and a change in fibre 
direction to form an apical helix with descending and 
ascending segments. This configuration equalizes stresses 
and strains across the ventricle [31, 32]. 
7. GEOMETRY AND FLOW DYNAMICS 
‘’ Blood flow in the heart is spirally twirled ‘’ 
Leonardo da Vinci 
  The deformation responsible for contractile strain 
increases from the widened base to the helical apex [33]. The 
pattern of ejection and filling are related to a sequential 
twisting of the LV to eject and a rapid untwisting to suction 
venous return and allow rapidly filling [34].  
  There is strong evidence that the transmission of flow 
into the aorta is helically shaped [35]. Consequently, spatial 
motion of flow in the LV and aorta closely resembles the 
pattern evident in typhoons or tornadoes. In contrast, there is 
destruction of helical flow in the dilated failing heart. 
  The elliptical shape formed by the overlapping ascending 
and descending segments of the apical loop accounts for the 
natural helix formation. With LV dilatation, the architecture 
of oblique apical loop fibres becomes more transverse, 
thereby resembling the horizontal fibre orientation of the 
basal loop. The value of reconstructing the helix to generate 
an elliptical shape [30] is emphasized because factors 
responsible for ejection and suction during the cardiac cycle 
are linked to this apical loop.  
7A. Functional Geometry 
  The cardiac architecture of the healthy heart is Gothic 
(elliptical), while that of the sick heart is Romanesque   
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(spherical) [36]. Ingels [28] emphasized the importance of 
the ‘opposing force couples’ from subendocardial fibres 
disposed in a right handed helix and subepicardial fibres in a 
left handed helix. The summation of these force couples 
generates the torsional deformation of the left ventricle about 
its long axis.  
8. PATHOLOGICAL SUBSTRATES 
  LV sphericity is the common architectural event 
following any disease that causes global stretch and results 
from one of three conditions.  
a   SVR in ischemic disease is based on recognizing the 
borders of the scar. The junction between scar and 
surrounding muscle determines patch placement. 
However, this transition zone ignores remote muscle 
dilatation, resulting in a large residual volume of dilated 
remote muscle and accounts for the poor long-term 
prognosis following restoration, if pre-operative end 
systolic volume index is >100-120 ml/m
2 [37]. In ventri-
cles without scar, SVR is not always performed. Isolated 
CABG, in these circumstances is associated with large 
post-operative volumes and poor outcomes [26].  
b    The absence of visible myocyte pathology in dilated 
hearts with valvular disease has so far precluded routine 
use of SVR. Outcomes remain poor following replace-
ment or repair when pre-operative EF is <40% [38].  
c   Non-ischemic cardiomyopathy from direct muscular 
involvement may stem from inflammation or sarcoi-
dosis. Non-ischemic cardiomyopathy is a heterogenous 
disease involving predominantly the septum and lateral 
wall [39]. Procedures such as partial left ventri-
culectomy failed due to the erroneous assumption that 
the disease was homogenous, with the consequent 
resection of healthy contractile lateral wall muscle in 
several cases.  
9. THERAPEUTIC ALTERNATIVES 
  The introduction of angiotensin-converting enzyme 
inhibitors, beta-blockers, aldosterone antagonists, HMG CoA 
reductase inhibitors, antiplatelet therapy, cardiac resynchro-
nization and implantable cardioverter defibrillators has 
reduced mortality from heart failure. 
  Even with optimal medical management, the mortality in 
patients with advanced HF is reportedly 40% to 50% at 1 to 
2 years. MacIntyre and colleagues demonstrated that mor-
tality among all-comers with CHF at 2 year approaches   
45% [40]. In the Randomized Evaluation of Mechanical 
Assistance for the Treatment of Congestive Heart Failure 
(REMATCH) trial, patients in NYHA IV demonstrated 25% 
survival at 1 year and 8% survival at 2 years with optimal 
medical management.  
10. SURGICAL ALTERNATIVES 
10 A. Coronary Revascularization 
  Patients with ischemic cardiomyopathy and a substantial 
amount of viable myocardium and a high end-systolic 
volume due to LV remodeling have a decreased likelihood of 
improvement of global function following myocardial 
revascularization or relief of heart failure symptoms.  
  The five-year survival of patients with EF 35% is 50% 
to 65% [41]. In one study, CABG mortality was 27% if LV 
end-diastolic diameter was 81 mm [42]. CHF symptoms are 
common after CABG for ischemic cardiomyopathy. 
Yamaguchi's analysis of CABG for patients with EF 30% 
showed a five-year survival of 54% with preoperative 
LVESVI  100 ml/m
2 compared to 85% if LVESVI was 
100 ml/m
2. CHF at five years was seen in 69% of patients 
with the larger hearts versus 15% with the smaller ones [43]. 
Luciani et al reviewed 167 patients who underwent CABG 
with a mean EF of 28%. At five years, 60% of patients 
continued to have signs and symptoms of CHF, demons-
trating the limitations of CABG alone [44].  
10 B. Mitral Valve Repair or Replacement 
  Patients with ischemic cardiomyopathy undergoing 
mitral procedures have a five-year mortality of approxi-
mately 50% [45]. Recurrence of CHF occurs in one-third of 
patients by five years and is the most common cause of 
death, presumably related to continuing dysfunction of the 
unmodified ventricle [38]. 
10 C. Partial Left Ventriculectomy 
  In 1995 Batista introduced partial left ventriculectomy to 
treat patients with non-ischemic dilated cardiomyopathy, by 
using a concept based on Laplace's law but results were 
variable due to non-specific exclusion of the lateral wall 
[46], which might have contained important viable muscle. 
Results were marred by (1) high surgical mortality, (2) 
concerns of diastolic dysfunction, (3) recurrent heart failure 
and (4) ventricular arrhythmias. While PLV had been 
performed to treat dilated cardiomyopathy [DCM], the 
hospital mortality varied between 1.9 and 27%, with a mean 
mortality of 17%. The causes of hospital death were CHF, 
hemorrhage, residual MR and multi-organ failure.  
10 D. Ventricular Assist  
  In the REMATCH trial, less than 10% of patients 
survived to three years in the LVAD group, compared with 
no survivors among patients treated medically [47]. The 
five-year survival after cardiac transplantation is 70%.  
10 E. Cardiac Transplantation 
  Cardiac transplantation offers the greatest benefit for 
patients with refractory heart failure, with a 1-year survival 
rate of 86% and a 5-year survival rate of 69%. With a limited 
donor organ pool and an increasing incidence of heart 
failure, this approach has limited application.  
11. SURGICAL VENTRICULR RESTORATION 
  In ischemic cardiomyopathy, the spherical geometry of 
the globally hypokinetic dilated heart leads to malfunction; 
hence contractility is not improved by simply restoring blood 
supply. Failure to change the natural course of progression of 
heart failure by isolated correction of coronary and/or valve 
pathology suggests that a ‘valve and ventricle’ approach 
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deranged without a triggering event; the elimination of the 
trigger (e.g., surgical reduction of pathologic cardiac 
wall stress) may result in neurohumoral inhibition.  
  In 1985, Vincent Dor described an original surgical 
technique, the Endoventricular Circular Patch Plasty [48] 
and subsequently reported excellent clinical and hemody-
namic results of this procedure [49].  
  Surgical ventricular restoration (SVR) is a surgical option 
designed to reverse the maladaptive morphologic changes of 
postinfarction ventricular remodeling, by restoring LV 
volume and a more normal elliptical shape to the LV, 
thereby reducing myocardial wall stress and improving 
ventricular function. SVR includes complete revascula-
rization, LV reconstruction to restore near-normal shape and 
volume and when necessary, mitral valve repair, in addition 
to surgery for ventricular tachycardia [VT]. This approach to 
HF has been considered the ‘triple V’ since the operation 
corrects the abnormal vascular, valvular and ventricular 
components of the heart failure process. 
12. SVR EVOLUTION 
  In the recent update of the European Society of 
Cardiology Guidelines for the diagnosis and treatment of 
chronic heart failure, LV aneurysmectomy is indicated in 
patients with large, discrete LV aneurysms who develop 
heart failure.  
  SVR as described by Dor and associates, was developed 
as a more physiologic repair of LV aneurysm, compared 
with simple linear repair, but was later applied to ischemic 
cardiomyopathy without the classic signs of the true 
aneurysm.  
  Dor demonstrated that equivalent results could be 
achieved with SVR even in patients without discrete 
ventricular aneurysms.  
  Dor [50] recognized that the adverse effects of 
remodeling on the remote non-infarcted myocardium were 
similar for akinesia and dyskinesia and was the first to utilize 
the endocardial patch plasty procedure for both morpho-
logies.  
13. SVR INDICATIONS 
  Indications for SVR include: 
1.  Refractory heart failure in NYHA class III or IV 
2.  A left ventricle diastolic dimension > 75 mm.  
3. LVESVI>60ml/m
2 
4. LVEDVI>100ml/m
2 
5.  Previous anterior MI.  
6.  LV dysfunction with regional asynergy (either akinetic 
or dyskinetic) greater than 35% of the ventricular 
perimeter. 
7.  Ventricular arrhythmias and/or angina. 
8.  For patients who are asymptomatic despite post-
infarction LV dysfunction, serial echocardiographic 
studies could be performed to detect the first signs of 
deterioration (i.e., progressive LV enlargement or 
decline in EF). 
14. CONTRAINDICATIONS 
  The following are contraindications:  
•  Severe right ventricular dysfunction (absolute) 
•  Severe pulmonary hypertension not associated with MR 
(relative). 
•  Severe regional asynergy without LV dilatation 
(absolute). 
•  Restrictive diastolic pattern associated with high 
functional class and MR (absolute). 
  An entirely akinetic LV with no increase in systolic wall 
thickness 
  Reduced EF is not a contraindication, but an increased 
use of IABP should be anticipated. With severe and diffuse 
cardiac dysfunction, a stress dobutamine stress echo could be 
performed. SVR is offered if contractility improves.  
15. EXTENDED INDICATIONS 
  Studies have shown that SVR can benefit patients with 
severe left ventricular dysfunction (EF <20%), multiterritory 
MI, and pulmonary hypertension [PHTN], which were 
previously considered to be contraindications to SVR [51-
53]. The survival of NYHA IV patients undergoing SVR is 
lower than those with milder HF, but still exceeds that of 
medically managed patients [40, 54].  
  SVR has also been offered to patients with multiterritory 
MI. A critical amount of viable myocardium is considered 
necessary for a successful outcome regardless of the location 
of infarction. For instance, patients with < 50% involvement 
of the lateral wall showed similar improvements in cardiac 
function and survival when compared with those without 
lateral wall MI’s. When lateral wall involvement exceeded 
50%, there were differences in clinical outcomes [55].  
  PHTN has been shown to be a predictor of death in 
patients with ischemic cardiomyopathy. However, improved 
LV function after SVR reduces the load on the pulmonary 
vasculature, and lowers pulmonary resistance and pressures.  
  A consideration of the real world application of ven-
tricular restoration procedures reveals that the overall results 
do not match those seen in large volume centres of expertise, 
and consequently the premature expansion of such 
indications outwith such centres of expertise could be 
potentially detrimental and may not yield equivalent 
outcomes in borderline patients.  
ABBREVIATIONS 
AII =  Angiotensin  II 
BNP  =  Brain natriuretic peptide 
CABG  =  Coronary artery bypass grafting 
CAD  =  Coronary artery disease 
CHF  =  Congestive heart failure 
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ICMPY =  Ischemic  cardiomyopathy 
IHD  =  Ischemic heart disease 
EF   =  Ejection fraction 
EVCPP  =  Endoventricular circular patch plasty 
DCM =  Dilated  cardiomyopathy 
GUSTO  =  Global Utilization of Streptokinase  
Trial     and Tissue Plasminogen Activator for  
   Occluded  Coronary  Arteries 
IABP  =  Intra aortic balloon pump 
ICD =  Implantable  cardioverter  defibrillator 
LAD   =  Left anterior descending artery 
LCX  =  Left circumflex artery 
LV   =  Left Ventricle 
LMI  =  Lateral wall myocardial infarction 
LVA  =  Left ventricular aneurysm 
LVESVI  =  Left ventricular end systolic volume  
   index 
LVESV  =  Left ventricular end systolic volume  
MI   =  Myocardial infarction 
MR   =  Mitral regurgitation 
MRI  =  Magnetic resonance imaging 
NE =  Norepinephrine 
NT-pro-BNP  =  N-terminal portion of proBNP 
NYHA  =  New york heart association 
PHTN   =  Pulmonary hypertension 
PLV =  Partial  left  ventriculectomy 
PRA  =  Plasma renin assay 
PTCA  =  Percutaneous transluminal coronary  
   angioplasty 
REMATCH   =  Randomized evaluation of mechanical  
    assistance for the treatment of  
    congestive heart failure 
RESTORE  =  Reconstructive Endoventricular Surgery  
Trial     returning Torsion Original Radius  
    Elliptical shape to the left ventricle 
RCA =  Right  coronary  artery 
RV =  Right  Ventricle 
SAVE  =  Septal Anterior Ventricular Exclusion 
procedure 
SAVE trial   =  Survival and ventricular enlargement 
STICH   =  Surgical treatment for ischemic heart  
   failure 
SVR   =  Surgical ventricular restoration 
VT =  Ventricular  tachycardia 
TOAT =  Open  artery  trial 
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